Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- diabetes -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (238)	9/8/2008 1:57:41 PM
From: keokalani'nui	Respond to of 278

content.nejm.org Here's the answer, from the paper: In the continuous-monitoring group, the use of sensors was greater among patients who were 25 years of age or older than in the other two age groups (P<0.001). The use of sensors was consistently high during the 26-week period among patients in the oldest age group but declined over time in the other two age groups (Figure 3). Excluding the three patients who dropped out, only one patient who was 25 years of age or older, seven who were 15 to 24 years of age, and two who were 8 to 14 years of age discontinued continuous glucose monitoring before completing the 26-week visit. At least 6.0 days of sensor use per week was the average for 83% of patients who were 25 years of age or older, 30% who were 15 to 24 years of age, and 50% who were 8 to 14 years of age. Sensor use was not associated with the baseline glycated hemoglobin level (Spearman's correlation coefficients, 0.08, –0.02, and 0.03 in the three groups, respectively).

To: keokalani'nui who wrote (238)	10/23/2008 9:03:47 AM
From: rkrw	Read Replies (2) \| Respond to of 278

Just when you think you've heard it all, someone comes out with an insulin suppository program. Press Release Source: Oramed Pharmaceuticals Inc. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository Thursday October 23, 8:30 am ET JERUSALEM, October 23 /PRNewswire-FirstCall/ -- - An Insulin Suppository Represents an Important Development in the Treatment of Diabetes as it Provides a Painless Alternative for Effective Insulin Delivery Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; oramed.com), a developer of alternative drug delivery systems, announced today that it has received approval from the South Africa Medicines Control Council (MCC) to begin conducting Phase 1A trials on eight healthy human volunteers for ORMD 0802, the company's newly developed insulin suppository. Oramed's Phase 1A trials on its insulin suppository mark an important step in the history of insulin delivery as it will provide a painless option for diabetics who seek an alternative to current delivery methods. An insulin suppository is especially important for small children and seniors, who often struggle with injections. "The Phase 1A trial of our insulin suppository is a natural expansion of Oramed's pursuit and development of alternative insulin delivery systems," said Oramed's CEO, Nadav Kidron. "By creating an insulin suppository, Oramed hopes to ensure that diabetics will be able to receive insulin in the form which is most suitable to their lifestyle and/or age." This Phase 1A trial follows Oramed's announcement of its successful Phase 2A clinical trials on its oral insulin capsule, ORMD 0801, which demonstrated that the product has a strong safety profile and was well tolerated, as well as being effective in lowering blood glucose levels, in patients with type 2 diabetes.